ASCO 2022 | Evaluating the mechanism of action of emavusertib

Bently Doonan, MD, University of Florida, Gainesville, FL, gives an overview of how emavusertib (CA-4948) can treat melanoma brain metastases. Emavusertib is an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), which decreases cancer proliferation vis decreased expression of NF-κB. The investigatory drug can also target brain metastases as it can pass the blood-brain barrier and has proven to be safe in patients with leukemia and lymphoma. Further research has indicated tumor regression is feasible with the addition of anti-PD-1 checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.